Chardan Capital analyst Keay Nakae maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) yesterday and set a price target of $4.00. The company’s shares closed yesterday at $2.20.
Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Coya Therapeutics, Inc., and Alnylam Pharma. According to TipRanks, Nakae has an average return of -3.9% and a 33.18% success rate on recommended stocks.
Arbutus Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
Based on Arbutus Biopharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.89 million and a GAAP net loss of $17.09 million. In comparison, last year the company earned a revenue of $12.56 million and had a GAAP net loss of $14.19 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
Read More on ABUS:
- Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Biopharma reports Q2 EPS (10c), consensus (11c)
- Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
- Is ABUS a Buy, Before Earnings?
